For direct compression of iodophenol-containing veterinary tablets, a pre-blend moisture limit below 2.0 % w/w is enforced before the compaction stage because the phenolic hydroxyl group can form a phenolate species in the presence of alkaline metal oxides and residual water, shifting tablet colour from off-white to tan and reducing assay recovery. A representative 250 mg tablet core contains iodophenol at 8.0 % w/w (20 mg), microcrystalline cellulose at 42.0 % w/w, lactose monohydrate at 45.0 % w/w, sodium starch glycolate at 4.0 % w/w, and magnesium stearate at 1.0 % w/w. The active powder is milled to a D90 below 150 µm; when particle size exceeds 180 µm, content uniformity failures under USP <905> and Ph. Eur. 2.9.40 become recurrent on single-punch and rotary tablet presses. Mixing is conducted in a 300 L bin blender at 12 rpm for 15 min, followed by a 3 min lubrication step. On a 16-station rotary press fitted with 9 mm round concave punches, the force window is 12–18 kN; tablets compressed below 12 kN show capping at the edge, while force above 18 kN elevates ejection friction and increases die wall wear when magnesium stearate is present at only 1.0 % w/w. The finished tablet hardness is maintained at 60–90 N, friability below 0.8 % under USP <1216>, and disintegration time below 15 min in water at 37 °C. Dissolution testing uses USP <711> apparatus 2 at 50 rpm in 900 mL of pH 6.8 phosphate buffer, with a specification of not less than 80 % released at 30 min. The tablet formulation is incompatible with pregelatinised starch sourced with high sodium content because the alkaline residue catalyses phenolate formation; lactose monohydrate is therefore preferred as the direct compression diluent.

Why Does Wet-Granulation Moisture Control Determine Dissolution Uniformity in Sachet Granules?

When a high-shear granulation train is configured for iodophenol oral granules, the binder addition rate and final loss-on-drying window are treated as critical process parameters because both alter the free phenolic fraction at the granule surface. A 5.0 % w/w aqueous povidone K30 solution is sprayed onto a dry blend containing iodophenol at 5.0 % w/w, mannitol at 70.0 % w/w, maize starch at 20.0 % w/w, and croscarmellose sodium at 5.0 % w/w. The wet mass is granulated in a 600 L high-shear mixer with impeller speed 150 rpm and chopper speed 1,500 rpm; addition of the binder solution over 8–10 min brings the wet mass LOD to 10–12 % w/w. Drying is performed in a fluid-bed dryer with inlet air at 60–65 °C, product temperature held at 35–40 °C, and final LOD between 1.5 % and 2.5 % w/w. Granules are passed through a 1.0 mm conical mill at 800 rpm. The finished granule fraction between 500 µm and 710 µm yields the fastest dissolution in 900 mL water at 25 °C, while fine particles below 150 µm dissolve quickly but segregate during sachet filling on auger machines, producing end-of-run net weight variation above 3.0 % RSD. In a production campaign involving 100 kg batches, content uniformity across 20 sachet samples is held at 95.0–105.0 % of label claim, with dissolution not less than 80 % at 15 min using USP <711> apparatus 2 at 50 rpm. Stability under 40 °C/75 % RH for 6 months in triple-laminate foil sachets shows no significant colour shift when the LOD remains below 2.5 %; batches dried below 1.0 % w/w exhibit electrostatic adhesion to the packaging line and lower assay values due to dust loss.

Inside a metric-ton ribbon blender used for medicated feed premix, the sequence of addition for milled calcium carbonate and iodophenol powder influences the coefficient of variation of the active assay more than total mixing time. A 10.0 % w/w active premix is produced by first adsorbing iodophenol onto fumed silica at 0.5 % w/w to reduce electrostatic clumping, then blending with calcium carbonate at 68.0 % w/w, wheat middlings at 19.5 % w/w, and soybean oil at 2.0 % w/w. The blender is filled to 60–70 % of working capacity; the main ribbon speed is 20 rpm and total mixing time is 20 min. Samples drawn from 10 positions after 15 min and 20 min show that a plateau CV of 3.8–4.5 % is reached only when the iodophenol-fumed silica blend is added after the calcium carbonate is charged. Reversing this order yields CV values above 7.0 % even at 25 min. Carryover into the next batch is controlled by a 25 kg calcium carbonate flush after discharge; residual iodophenol in the subsequent batch is maintained below 0.1 % of the previous batch assay. The carrier and soy oil are specified against VICH GL18 residual solvent limits and VICH GL11 impurity thresholds. For incorporation into finished feed, the 10.0 % premix is metered at 10 kg per tonne to deliver an active concentration of 1,000 mg/kg. Cross-contamination limits follow FDA 21 CFR Part 558 principles for medicated feed additives, with cleaning validation acceptance at not more than 10 ppm active carryover in the next non-medicated batch. The finished premix is filled into 25 kg multi-wall paper bags with polyethylene liners; storage is at or below 25 °C and 60 % RH, with a retest period of 24 months.

Sterile Injectables Are Constrained by Filter Compatibility and Ionisation State

Terminal filtration of iodophenol injectable solution through a 0.22 µm polyvinylidene difluoride capsule filter is validated only after a pH shift from 8.5 to 6.5, because the ionised phenolate form at higher pH is more surface-active and binds to filter membrane polymers, reducing recovery. A vehicle consisting of propylene glycol at 40.0 % v/v, ethanol at 10.0 % v/v, and water for injection qs to 100 mL is used for an iodophenol concentration of 5.0 mg/mL. The solution is adjusted to pH 6.5 with 0.1 M citrate buffer; tonicity is adjusted with mannitol at 5.0 % w/v. Sterilisation is by aseptic filtration through a 0.22 µm PVDF capsule, pre-washed with 2 L of vehicle to reduce extractables. The filtered volume per 10-inch capsule is limited to 50 L before replacement to avoid filter clogging caused by phenolic vehicle interaction products. Fill volume is 10.5 mL into 20 mL amber glass vials with chlorobutyl stoppers; headspace oxygen is reduced by nitrogen overlaying at 0.5 bar. Sterility testing follows USP <71> direct inoculation; bacterial endotoxin limit is set at not more than 0.5 EU/mg unless a higher limit is justified by the target species. Parenteral use of iodophenol as an active in food-producing species is constrained by the absence of a published maximum residue limit in many jurisdictions; therefore, this dosage form is primarily evaluated in companion animal programmes where residue depletion is not applicable. Published data for this specific injectable configuration is limited, and filter compatibility, haemolytic potential, and injection-site irritation require batch-specific confirmation. The solution should not be mixed with saline diluents containing phenolic antioxidants or with amine-based buffers above pH 7.5.

A dry blending operation for iodophenol oral powder at 5.0 % w/w active is conducted in a 500 L V-blender under 30–35 % RH to prevent phenol oxidation and moisture uptake on dextrose monohydrate. The formulation contains iodophenol at 5.0 % w/w, citric acid anhydrous at 12.0 % w/w, sodium bicarbonate at 18.0 % w/w, dextrose monohydrate at 60.0 % w/w, and colloidal silicon dioxide at 1.0 % w/w. The active is first geometrically diluted with 2 kg of dextrose monohydrate through a 500 µm sieve before being added to the main blender; this step reduces active assay CV from above 9.0 % to below 4.0 % in direct comparisons. The blend is mixed for 20 min at 15 rpm, then discharged through a 1.0 mm grille. Sachet filling on a volumetric auger machine produces 20 g fill weights with a net content variation below 2.5 %. Dissolution of a 20 g sachet in 1 L simulated drinking water at 25 °C is complete within 90 s; the pH after reconstitution is 5.0–5.5, which keeps iodophenol in its molecular form without causing gastrointestinal irritation. Long-term stability in aluminium foil sachets at 25 °C/60 % RH for 24 months shows assay remaining at 96.8–101.2 % when the sachet is impermeable to oxygen. In high-humidity packaging lines above 60 % RH, the citric acid-sodium bicarbonate effervescent pair pre-reacts, causing sachet bloating and a drop in dissolution speed; production is therefore scheduled only when the packaging hall is controlled below 35 % RH.

Solubility-Guided Co-Solvent Ratios for Drinking Water and Topical Solutions

For drinking water and topical solutions, aqueous solubility of the iodophenol active is insufficient to achieve a therapeutic concentration without cosolvents, so propylene glycol and glycerin are combined with water in mass ratios that alter the dielectric constant and suppress phenolate ionisation. A drinking water solution is formulated at 2.0 % w/v iodophenol using propylene glycol at 30.0 % v/v, glycerin at 10.0 % v/v, and purified water qs to 100 mL. Sodium metabisulfite at 0.1 % w/v and disodium edetate at 0.01 % w/v are added to reduce oxidative coupling. The solution is adjusted to pH 4.8–5.2 with 0.1 M citric acid; at pH above 6.5, the phenolic group ionises and the solution develops a yellow-brown colour within 72 h at 25 °C. A topical iodophenol solution at 5.0 % w/v uses ethanol at 55.0 % v/v, glycerin at 10.0 % v/v, and purified water qs to 100 mL; this higher ethanol fraction provides rapid evaporation on animal skin and reduces the activity of water below 0.7. Both solutions are filled into amber Type III glass bottles and stored below 25 °C; photostability under ICH Q1B conditions is evaluated for not less than 1.2 million lux·h visible light and 200 W·h/m² UV. The finished solution must remain clear and free of visible precipitates after 3 freeze-thaw cycles from -5 °C to 40 °C. For drinking water administration, a 100 mL aliquot diluted in 10 L water should produce a pH between 5.0 and 5.5; deviations above 6.0 indicate that alkalinity in the source water is consuming the buffer and requires acidification before dosing.

When Hard Gelatin Capsule Cross-Linking Is Observed During Accelerated Stability

Accelerated stability protocols for hard gelatin capsules containing 10 mg iodophenol per shell often fail dissolution specifications at the 3-month time point when the fill excipient includes maize starch with residual aldehyde impurities; the aldehyde groups cross-link gelatin lysine residues, forming a pellicle that delays capsule rupture. A fill blend comprising iodophenol at 5.0 % w/w, pregelatinised starch at 80.0 % w/w, talc at 4.0 % w/w, and magnesium stearate at 1.0 % w/w is filled into size 3 hard gelatin capsules on a 100,000 capsules per hour dosator machine. The active is screened through a 300 µm sieve before blending; blend uniformity across 10 sampling points remains below 3.0 % RSD when the blender speed is 12 rpm and the fill time is 15 min. Capsule moisture is held at 12.0–14.0 % w/w; below 11.0 %, the gelatin shells become brittle during automated handling, and above 15.0 %, the fill powder may adhere to the inner wall. At 40 °C/75 % RH in HDPE bottles with desiccant, dissolution using USP <711> apparatus 2 with 0.1 M hydrochloric acid at 50 rpm shows 85–95 % release at 30 min at initial, but values drop below 70 % when the desiccant is insufficient to keep the capsule LOD below 12.0 %. If cross-linking is observed, the two-tier dissolution protocol with pepsin at 750 U/mL in 900 mL water is used to distinguish shell-related failure from active-related precipitation. The capsule formulation is not suitable for combination with aldehyde-functional excipients such as some pregelatinised starches above 10 % w/w, and it should not be stored above 30 °C for extended periods.